drugset / Trial / NCT03688971

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

NCT03688971

Phase 2 Unknown 36 enrolled Maruho Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.

Timeline

Start
2018-10-22
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketoconazole Small molecule 2 % Topical
Subject Omiganan Protein / enzyme biologic 1.75 % Topical

Indications